24.02.2016
Fresenius SE & Co. KGaA DE0005785604
DGAP-Adhoc: Fresenius SE & Co. KGaA: Outstanding 2015 financial results - 25% dividend increase proposed - Positive Group guidance for 2016 - New stretch targets for 2019
Fresenius SE & Co. KGaA / Key word(s): Forecast/Final Results
24.02.2016 07:00
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Group sales increased by 19% (9% in constant currency) to EUR27,626 million
(2014: EUR23,231 million). Organic sales growth was 6%. Acquisitions
contributed 4% and divestitures reduced sales by 1%. Currency translation
had a positive effect of 10%.
Group EBIT* increased by 25% (13% in constant currency) to EUR3,958 million
(2014: EUR3,158 million). The EBIT margin* increased to 14.3% (2014:
13.6%).
Group net income** before special items increased by 31% (21% in constant
currency) to EUR1,423 million (2014: EUR1,086 million). Earnings per
share** before special items increased by 30% (20% in constant currency) to
EUR2.61 (2014: EUR2.01).
Group net income** including special items increased by 27% (17% in
constant currency) to EUR1,358 million (2014: EUR1,067 million). Earnings
per share** including special items increased by 27% (16% in constant
currency) to EUR2.50 (2014: EUR 1.97).
Based on the strong financial results, the Management Board will propose to
the Supervisory Board a dividend increase of 25% to EUR0.55 per share
(2014: EUR0.44).
For 2016, Fresenius projects sales growth of 6% to 8% in constant currency.
Net income*** is expected to grow by 8% to 12% in constant currency.
For 2019, Group sales are expected to reach EUR36 billion to EUR40
billion****. Group net income** is expected to increase to EUR2.0 billion
to EUR2.25 billion****.
* Before special items
** Net income attributable to shareholders of Fresenius SE & Co. KGaA
*** Net income attributable to shareholders of Fresenius SE & Co. KGaA;
2015 before special items
**** At comparable exchange rates; including small and mid-size
acquisitions
(Financial statements according to U.S. GAAP)
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management
Bad Homburg v.d.H., February 24, 2016
End of note
24.02.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: [email protected]
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard),
Munich; Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Stuttgart; Terminbörse EUREX
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Fresenius SE & Co. KGaA ISIN: DE0005785604 können Sie bei EQS abrufen
Medtech , 578560 , FRE , XETR:FRE